New Parkinson's Drug Tavapadon Extends Daily Good Movement Time by 1.1 Hours
Novel D1/D5 receptor agonist shows promise for reducing motor fluctuations in Parkinson's patients with fewer side effects.
Parkinson's disease, dopamine pathways, movement disorders, and neuroprotection
109 articles
Novel D1/D5 receptor agonist shows promise for reducing motor fluctuations in Parkinson's patients with fewer side effects.
Researchers discover TMEM175, a cellular safeguard that prevents toxic buildup linked to Parkinson's when it malfunctions.
Five large studies reveal dairy as the strongest dietary risk factor for Parkinson's disease, with potential brain cell damage mechanisms identified.
New research reveals five ways microscopic plastic particles could damage brain health and accelerate neurodegenerative diseases.
Moderate caffeine intake from coffee or tea linked to better brain health and slower cognitive decline in massive long-term study.
Scientists used red blood cells to transport healthy mitochondria into diseased brain cells, showing promise for Parkinson's treatment.
Mayo Clinic study reveals how early estrogen treatment affects brain blood flow and cognitive aging in postmenopausal women.
Clinical trial explores whether resetting gut microbiome through fecal transplants can slow Parkinson's progression and reduce symptoms.
Study tests whether fasting before or after soccer heading reduces brain injury markers and cognitive impairment in college athletes.
60-patient trial explores whether metformin, combined with standard therapy, could slow Parkinson's progression through metabolic pathways.
Neuroscientist David Eagleman reveals how neuroplasticity works and practical strategies to optimize learning and memory at any age.
Neuroscientist Dr. Read Montague reveals how dopamine functions as a learning algorithm, not just reward system.